ArticleDiscover oncology2025
Multi-omics approaches including single-cell analysis and machine learning were used to identify the roles of telomere-related genes in esophageal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTelomeres, consisting of TTAGGG repeats and six shelterin proteins, have been extensively studied in oncogenesis due to their crucial role in maintaining genomic stability. Despite these advances, the prognostic significance of telomere-related genes (TRGs) in esophageal squamous cell carcinoma (ESCC) remains poorly characterized.
methodsTranscriptomic data, single-cell RNA sequencing (scRNA-seq) data, and clinical information of ESCC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. TRGs were retrieved from the TelNet database. Core TRGs were identified using three machine learning algorithms: least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), and random forest (RF). Based on prognosis-related TRGs, unsupervised clustering was performed to classify ESCC patients into two distinct molecular subtypes, and a prognostic risk model was subsequently constructed. Following risk stratification, survival analysis, immune infiltration analysis, drug sensitivity analysis, and molecular docking were conducted to further evaluate the potential clinical value of the risk model in ESCC. In addition, the expression patterns and intercellular communication of the model genes were examined using single-cell data. Finally, the differential expression of the core genes was validated by quantitative real-time PCR (qRT-PCR).
resultsWe developed a prognostic risk prediction model using five independent prognostic TRGs. The model demonstrated excellent performance in predicting patient outcomes and effectively revealed the heterogeneity of the tumor immune microenvironment (TIME). Drug sensitivity analysis indicated that ribociclib was more effective in the high-risk group. Single-cell analysis revealed the distribution of the five genes across cellular subpopulations. The qRT-PCR results further validated the differential expression of the core genes.
conclusionThrough a systematic analysis of TRGs expression patterns, we successfully developed a prognostic prediction model that effectively captures the heterogeneity in survival outcomes, TIME characteristics, and drug sensitivity among patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.